Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
BMEA Stock Chart & Stats
$1.34
$0.07(1.75%)
At close: 4:00 PM EST
$1.34
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$0.87 - $4.59
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$94.74M
Enterprise Value$23.96M
Total Cash (Recent Filing)$46.64M
Total Debt (Recent Filing)$6.88M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Apr 06, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding70,703,636
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-47.93
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$7.75Price Target Upside478.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination Therapy And Lean Mass PreservationPreclinical and early clinical signals that icovamenib enhances GLP‑1 activity while preserving lean mass suggest potential value as a combination approach to improve weight and metabolic outcomes without worsening muscle loss.
Disease-modifying EfficacySustained increases in C-peptide and persistent HbA1c improvements after treatment discontinuation support the potential for a disease‑modifying profile in insulin‑deficient diabetes patients.
Targeted Clinical Response In SIDD And Post-GLP-1 PatientsClinically meaningful HbA1c reductions observed in severe insulin‑deficient and post‑GLP‑1 nonresponder cohorts indicate targeted benefit in hard‑to‑treat type 2 diabetes subtypes and strengthen the case for focused Phase 2 trials.
Bears Say
Biomarker And Patient Selection UncertaintyAbsence of mechanistic biomarkers to validate long‑term disease modification and reliance on a T2D subtype framework not routinely used in practice complicate regulatory alignment and real‑world patient identification.
Financing And Dilution RiskFunding concerns and dilution from the public offering create a financing overhang that could weigh on the stock and limit flexibility for ongoing and planned studies.
Operational Expense PressureHigher‑than‑expected operational expenses have driven analyst valuation reductions and increase execution risk as the company advances multiple clinical programs.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $4.59 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $94.74M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Apr 06, 2026 which is in 86 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Nov 04, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.256 by -$0.014.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.23.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 70,703,636 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.256. Following the earnings report the stock price went up 6.349%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.75 (478.36% Upside)
$7.75 (478.36% Upside)
Hedge Fund Trend
Decreased
By 443.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $196.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
-209.00%
Trailing 12-Months
Asset Growth
-46.27%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.75
▲(478.36% Upside)
Technical Analysis
Ownership Overview
8.85% Insiders
10.12% Mutual Funds
15.05% Other Institutional Investors
61.75% Public Companies and
Individual Investors